


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

NOTICE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Friday, 27 March 2026, for the purposes of considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2025 and its publication and considering the recommendation on the payment of a final dividend, if any.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, 17 March 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Mr. Liu Min and Ms. Xiao Jieyu as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qionguang as independent non-executive Directors.